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Abstract
Lung cancer is the most common cause of death from 
cancer in males, accounting for more than 1.4 million 
deaths in 2008. It is a growing concern in China, Asia 
and Africa as well. Accurate staging of the disease is an 
important part of the management as it provides esti-
mation of patient’s prognosis and identifies treatment 
sterategies. It also helps to build a database for future 
staging projects. A major revision of lung cancer stag-
ing has been announced with effect from January 2010. 
The new classification is based on a larger surgical and 
non-surgical cohort of patients, and thus more accurate 
in terms of outcome prediction compared to the previ-
ous classification. There are several original papers 
regarding this new classification which give comprehen-
sive description of the methodology, the changes in the 
staging and the statistical analysis. This overview is a 
simplified description of the changes in the new classifi-
cation and their potential impact on patients’ treatment 
and prognosis.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
Lung cancer is the most common cause of  cancer 
deaths in males, accounting for 13% (1.6 million) of  the 
total cancer cases and 18% (1.4 million) of  the cancer 
deaths in 2008. Male lung cancer death rates are decreas-
ing in the western world and increasing in China and 
several other countries in Asia and Africa. Female lung 
cancer death rates are increasing worldwide, with the ex-
ception of  United States, Canada and Australia[1-3].
Complete resection of  lung cancer is associated with 
significantly longer survival remission but only about 
25% of  patients are candidates for surgical treatment at 
the time of  diagnosis[4]. Staging of  cancer at the time of  
diagnosis is the most important predictor of  survival, and 
treatments options should be based on the stage. Since 
the introduction of  tumour, node, metastasis (TNM) 
staging by Pierre Denoix between the years 1943 and 
1952, there have been significant changes including the 
TNM staging for lung cancer. The International Union 
Against Cancer (UICC) TNM Prognostic Factors Project 
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continued to develop the TNM classification as more data 
became available. The pocket book, “Livre de Poche”, 
was the first edition of  the TNM classification and was 
published in 1968 and following several updates, the sixth 
edition was released in 2002. Like other tumours, lung 
cancer classification and staging assess the anatomical 
extension of  the tumor which is critical to choosing a 
therapy and provides information on prognosis[5-9].
The International Association for the Study of  Lung 
Cancer (IASLC) announced a major revision of  the 
TNM staging system for lung cancer[10]. This has been in-
cluded in the seventh edition of  the “TNM classification 
of  malignant tumours” published by the UICC in January 
2010 (Table 1). The previous latest update of  the clas-
sification was based on a predominantly surgical database 
of  5319 patients from a single centre in the United States 
from 1972 to 1988[11]. The database was small and old 
and there was little internal and no external validation of  
stage groupings relating to these data and given the fact 
that this is the commonest cause for cancer related death, 
a major revision of  the staging was long overdue and 
became possible with the availability of  multicentre and 
larger cohorts of  patients being treated for lung cancer.
Traditionally the TNM classification has been used 
for non-small-cell lung cancer (NSCLC). Even though 
the TNM classification was applicable to the small-cell 
lung cancer (SCLC), this was not practiced. SCLC was 
classified as “local” and “extensive” disease. The new 
classification is also applicable to both types of  lung can-
cers[12].
Imaging has a fundemental role in staging of  the lung 
cancer. As imaging techniques have improved especially 
in terms of  resolution and speed for CT scans and as 
newer techniques like positron emission tomography 
(PET) have become established in the routine clinical 
practice, consideration needed to be given to revising the 
classification and staging of  lung cancer. The new clas-
sification has led to alteration in treatment options and in 
predicting the prognosis.
The staging of  lung cancer can be clinical or patho-
logical (also known as surgical). Clinical staging involves 
radiological studies (plain radiographs and CT scan).
Currently, PET (Figure 1) is routinely used in many 
centres as an additional diagnostic tool which may change 
the clinical stage of  the disease in a given patient. PET 
often upstages the disease (in comparison to convention-
al CT scan) by identifying newer, metabolically active sites 
of  disease (Figure 2). In a minority of  cases, it down-
stages the disease (Figure 3). However, it must be noted 
that the database analysed for the 7th TNM classification 
did not include any data from PET studies. Surgical stag-
ing refers to pathological staging following surgery or 
tissue biopsy (e.g., via endoscopical techniques). In addi-
tion to T, N and M descriptors, the pathological staging 
also involves description of  resection margins which is 
indicated as R0 or R1 (R0 is resection margins clear of  
the malignancy and R1 is involved margins). Following 
pathological staging, the T, N and M become pT, pN 
and pM. Obviously, this may result in either upward or 
downward alteration of  clinical staging. The overall level 
of  agreement between clinical and pathological systems 
is reported to be only 35%-55%[13].
The aim of  this overview is to discuss the basis for 
the changes in the 7th classification of  lung cancer and 
its impact on predicting patients’ prognosis. Potential 
limitations of  the classification and future directions are 
discussed.
APPROACH TO DEVELOPMENT OF THE 
7TH TNM CLASSIFICATION
A retrospective international lung cancer database was 
developed from 46 sources in more than 19 countries 
with staging and outcome data on 100 869 lung cancer 
cases managed between 1990 and 2000. After applying 
exclusion criteria, 81 015 cases remained for analysis. 
Of  these, 67 725 were NSCLC and 13 290 were SCLC. 
Only the NSCLC cases were included in the analyses of  
the T, N and M descriptors and the subsequent analysis 
of  TNM subsets and stage groupings[10]. From 67 725 
NSCLC cases, 38265 were clinically without metastases, 
and 28 371 had pathological staging (defined at thora-
cotomy). Survival was estimated by the Kaplan-Meier 
method. Prognostic groups were assessed by Cox regres-
sion analysis after adjustment for cell type, sex, age and 
region, using the SAS System for Windows Version 9.0 
PHREG procedure[10,14].
New tumour staging
The T staging is determined by the size of  primary tu-
mour in long axis, or direct extent of  the tumour into 
adjacent structures such as mediastinum or chest wall.
Main changes in staging classification are reflected 
in the T staging. These changes are largely related to the 
re-classification of  the size and location of  the primary 
tumour and satelite nodules (Table 2).
The former staging system divided tumours into two 
size groups with 3 cm as the cut off  point. The new sys-
tem has 5 size-based categories with cut-off  points at 2, 
3, 5 and 7 cm. Tumours measuring < 2 cm are classified 
as T1a, whereas those measuring 2-3 cm are classified as 
T1b. T2 disease is also subdivided into T2a (> 3 - 5 cm) 
and T2b (> 5 cm - 7cm). The tumours larger than 7 cm 
are now classified as T3. The additional cut-off  points 
changes may alter treatment recommendations.
The new calssifcation does not take into account a 
single tumour which involves two lobes across a fissure. 
It only considers the tumour size and satellite (non-con-
tagious) nodules in the same and different lobes. Patients 
previously considered T4 if  additional tumour nodules 
were found in the same lobe are now classified as T3. Ad-
ditional tumour nodules outside the primary lobe but in 
the same lung, are now down staged from M1 to T4 and 
they may be suitable for a pneumonectomy. Classification 
for a satellite nodule in the contralateral lung has changed 
from M1 to M1a to indicate intrathoracic spread, which 
has a slightly favourable prognosis compared to patients 
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T: Tumour 
   TX Primary tumour cannot be assessed, or tumour proven by the presence of malignant cells in sputum or bronchial washings but not visualized 
by imaging or bronchoscopy 
   T0 No evidence of primary tumour 
   Tis Carcinoma in situ 
   T1 Tumour < 3 cm in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than 
the lobar bronchus (i.e., not in the main bronchus) 
      T1a Tumour < 2 cm in greatest dimension 
      T1b Tumour > 2 cm but < 3 cm in greatest dimension 
   T2 Tumour > 3 cm but < 7 cm or tumour with any of the following features (T2 tumours with these features are classified T2a if < 5 cm): 
Involves main bronchus, > 2 cm distal to the carina 
Invades visceral pleura 
Associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung 
      T2a Tumour > 3 cm but < 5 cm in greatest dimension 
      T2b Tumour > 5 cm but < 7 cm in greatest dimension 
   T3 Tumour > 7 cm or one that directly invades any of the following: 
Chest wall (including superior sulcus tumours), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium 
Tumour in the main bronchus < 2 cm distal to the carina but without involvement of the carina
Associated atelectasis or obstructive pneumonitis of the entire lung 
Separate tumour nodule(s) in the same lobe 
   T4 Tumour of any size that invades any of the following: 
Mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina
Separate tumour nodule(s) in a different ipsilateral lobe 
N: Nodes 
   NX Regional lymph nodes cannot be assessed 
   N0 No regional lymph node metastasis 
   N1 Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension 
   N2 Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s) 
   N3 Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s) 
M: Metastases 
   MX Distant metastasis cannot be assessed 
   M0 No distant metastasis 
   M1 Distant metastasis 
      M1a Separate tumour nodule(s) in a contralateral lobe 
tumour with pleural nodules or malignant pleural/ pericardial effusion 
      M1b Distant metastasis 
Table 1  Seventh tumour, node, metastasis classification of lung cancer: January 2010 [10] 
Figure 1  Contrast enhanced com­
puted tomography of the chest view­
ed with mediastinal window settings 
demonstrated a large necrotic mass 
in the right upper lobe (A) with en­
larged necrotic paratracheal lymph 
nodes in station 4R (arrowhead) (B). 
C, D: Positron emission tomography-
computed tomography demonstrated 
high [18F]-2-fluoro-2-deoxy-d-glucose-
uptake in the mass and lymph nodes 
confirming a T2aN2 lung cancer. 
A B
C D
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Figure 2  Contrast enhanced thoracic computed tomography viewed with lung window settings shows a 5.2 cm ill-defined mass suspected of lung cancer 
abutting the right lung hilum, causing narrowing of the upper lobe bronchus (A). B: Review of images on mediastinal window settings showed a paratracheal 
lymph node with short axis smaller than 1 cm (arrow) in station 2R; C and D: Positron emission tomography-computed tomography demonstrated a high [18F]-2-
fluoro-2-deoxy-d-glucose-uptake of both mass and 2R node (arrowhead), resulting in an up-staging of the disease from T2bN1 (CT classification) to T2bN2. This find-
ing was further confirmed by mediastinoscopy sampling. 
A B
C D
Figure 3  Example of cross sectional imaging nodal staging pitfalls. A: A mass of the right lung (arrow) was identified on chest radiograph. B: A 4 cm spiculated 
mass suspected of lung cancer in the right upper lobe was confirmed by computed tomography (CT); C, D: Contrast enhanced CT demonstrated enlarged lymph nodes 
(> 1 cm in short axis; arrowheads) in ipsi- and contra-lateral mediastinal nodal stations (C) (T2aN3), positron emission tomography-computed tomography (PET-CT) (D) 
showed high metabolic activity of the parenchymal lesion but no nodal [18F]-2-fluoro-2-deoxy-d-glucose uptake (PET-CT staging: T2aN0M0). No metastatic nodes were 
demonstrated by endoscopic ultrasound-needle aspiration and mediastinoscopy, and surgical staging was in full agreement with PET-CT (pT2N0 adenocarcinoma). 
A B
C D
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with distant metastases (M1b). Figures 4 to 6 show ex-
amples of  cases in whom the new T classification has 
changed the staging.
New node staging 
The N classification descibes the degree of  spread to re-
gional lymph nodes. This remained unchanged in the 7th 
edition as the new data showed no change in node stag-
ing related survival.
The regional nodal classification for lung cancer was 
described by Mountain and Dresler (1997)[15]. Various 
techniques are used to identify nodal spread. Previous 
studies showed that the sensitivity and specificity of  CT 
and PET for predicting malignant involvement of  me-
diastinal lymph nodes were 60% and 81%, and 84% and 
89%, respectively[16]. Lymph node sampling is regarded as 
the most accurate predictor of  nodal status. Mediastinos-
copy has been regarded as the “gold standard” for staging 
of  the mediastinum, but it is invasive and has limitations 
in accessing to the posterior and inferior mediastinal 
nodes. Furthermore, the sensitivity for mediastinoscopy 
is still only 80%-90%, and, in 10%-15% of  cases, the 
technique returns a false-negative diagnosis[17,18].
Endobronchial ultrasound-guided transbronchial 
needle biopsy (EBUS-TBNA) is reported to have a sen-
sitivity of  85% and a negative predictive value of  90%[19]. 
Similarly, Rintoul et al[20] reported a sensitivity, specific-
ity and accuracy of  85%, 100% and 89%, respectively 
for EBUS-TBNA. They also suggested that a combined 
EBUS and oesophageal endoscopic ultrasound (EUS) 
allows better access to the mediastinal and hilar lymph 
nodes than is usually accessible by mediastinoscopy[20]. 
A further study of  150 consecutive lung cancer patients 
reported that combination of  EUS fine needle aspiration 
(EUS-FNA) and EBUS-TBNA had higher sensitivity 
(93%) and higher negative predictive value (97%), when 
compared to that of  each technique[21]. This however 
needs to be highlighted that not all lymphnode stations 
are not accessible by EUS techniques.
New metastasis staging
The M staging defines the presence of  metastases beyond 
regional lymph nodes. In the 7th edition of  the lung can-
cer classification, the pleural or pericardial dissemination 
(effusions or nodules) are no longer classified T4, but are 
now upstaged into a new category (M1a). This category 
also includes additional nodules that are found in the 
contralateral lung. Distant metastasis is sub-classified as 
M1b disease.
Table 2 Summary of what has changed 
Feature Old - sixth 
classification 
2002-2009 
Current, new - 
seventh classification 
- Jan 2010 
Tumour < 2 cm T1 T1a 
Tumour > 2  but < 3 cm T1 T1b 
Tumour > 3 cm but < 5 cm T2 T2a 
Tumour > 5 but < 7 cm T2 T2b 
Tumour > 7 cm T2 T3 
Tumour - same lobe nodules T4 T3 
Ipsilateral lung nodule - non 
primary lobe 
M1 T4 
Malignant pleural effusion T4 M1a 
Contralateral lung nodule M1 M1a 
Distant metastases M1 M1b Figure 4  A 2.5 cm mass (arrow) in the right lower lobe was classified as 
T1 in 6th edition and is described as T1b in the 7th classification. This did 
not change the staging (see Table 3). 
Figure 5  A 7.5 cm necrotic mass in the right lower lobe (arrow). As far as 
size is concerned, the T classification is upstaged from T2 to T3 and therefore a 
worse prognosis is expected. 
A B
Figure 6  Example of change in classification status. A: A mass in the right 
upper lobe and a satellite nodule (arrow) in the right middle lobe. This tumour is 
reclassified from M1 to T4. Patient may be considered for treatment (e.g., pneu-
monectomy) and a better prognosis is to be expected; B: A tumour with a satel-
lite nodule (arrowhead) both in right lower lobe; this was therefore downstaged 
from T4 to T3 in the new classification and surgical treatment was considered.  
Mirsadraee S et al . The 7th lung cancer TNM classification
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M1a includes malignant pleural effusion (with median 
overall survival of  8 mo in 488 patients) and contralateral 
lung nodules, which had overall survival of  10 mo in 362 
patients. M1b refers to extra-thoracic metastases and me-
dian overall survival was 6 mo (n = 4343). This contrasts 
with 13 mo overall median survival in T4M0 any N group 
(n = 399)[22]. Figure 7 shows an example in which the new 
TNM classification has changed the T and M staging.
Impact of new staging system on patient management 
The revised lung cancer staging based on the new TNM 
classification is shown in Table 3[10].
New staging is based on analyzing survival in large 
databases based on tumour size and disease proliferation 
and therefore is expected to assess an individual patient’
s prognosis more accurately. Many patients will receive 
a different staging category based on the 7th edition of  
the TNM staging system. Those who are down-staged 
because additional tumours are found in the same lobe as 
the primary tumour may now be considered candidates 
for adjunctive chemotherapy along with surgery. Similarly, 
there may be a greater role for surgery in patients with 
metastatic nodules in the ipsilateral, non-primary lobe 
who previously would have been assigned a stage Ⅳ diag-
nosis, but are now stage ⅢA.
Those patients who undergo biopsy or surgical resec-
tion of  the tumour and/or lymph nodes may have their 
TNM classification revised based on histological find-
ings. The clinical staging of  the patient thus changes into 
pathological staging and is described by adding prefix “p” 
e.g., T1b N1 M0 may become pT2a pN2 M0 based on 
pathological measurements and findings, and these would 
influence treatment strategies and estimated prognosis.
Limitations of new classification
There are glaring deficiencies in the global distribution of  
the data with no data at all being included from Africa, 
South America or the Indian subcontinent. Other vast 
countries such as Russia, China, and Indonesia are not 
represented or only poorly represented[10]. Moreover, the 
database used for the 7th edition of  lung staging classifi-
cation (1990-2000) predates the widespread and routine 
use of  PET which has had an enormous impact on clini-
cal staging algorithms[10].
Lympahngitis carcinomatosis (Figure 8) is believed 
to be associated with worse prognosis in lung cancer 
patients. However, there is no evidence to support this. 
The new TNM classification does not specifically take ac-
count of  lymphangitis.
Figure 7  A patient with a necrotic mass in the right lower lobe (short ar­
row). As seen in this axial contrast enhanced computed tomography, there is 
pleural (p) and pericardial (pc) effusions which were confirmed to be malignant. 
This will be re-classified from T4 to M1a indicating worse estimated prognosis. 
Figure 8  Lymphangitis caused by a large right upper lobe mass, note 
thickening of interlobular septa (arrowhead) and perilobular nodules (ar­




Table 3  Changes in the staging of lung cancer based on the 
new tumour, node, metastasis classification: Cells in the bold 
indicate a change from the sixth edition  for a tumour, node, 
metastasis category[10]




N0 N1 N2 N3 
T1 (≤ 2 cm) T1a Ⅰ A Ⅱ A Ⅲ A Ⅲ B 
T1 (> 2-3 cm) T1b Ⅰ A Ⅱ A Ⅲ A Ⅲ B 
T2 (≤ 5 cm) T2a Ⅰ B Ⅱ A Ⅲ A Ⅲ B 
T2 (> 5-7 cm) T2b Ⅱ A Ⅱ B Ⅲ A Ⅲ B 
T2 (> 7 cm) T3 Ⅱ B Ⅲ A Ⅲ A Ⅲ B 
T3 (invasion) T3 Ⅱ B Ⅲ A Ⅲ A Ⅲ B 
T4 (same lobe nodule) T3 Ⅱ B Ⅲ A Ⅲ A Ⅲ B 
T4 (extension) T4 Ⅲ A Ⅲ A Ⅲ B Ⅲ B 
M1 (ipsilateral non 
primary lobe nodule) 
T4 Ⅲ A Ⅲ A Ⅲ B Ⅲ B 
T4 (pleural effusion) M1a Ⅳ Ⅳ Ⅳ Ⅳ 
M1 (contralateral lung 
nodule) 
M1a Ⅳ Ⅳ Ⅳ Ⅳ 
M1 (distant metastases) M1b Ⅳ Ⅳ Ⅳ Ⅳ 
p
pc
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WHAT NEXT FOR LUNG CANCER 
STAGING?
The process by which TNM classification in lung cancer 
evolves has been changed irrevocably, and the IASLC has 
secured a central role in future revisions for the whole of  
the thoracic oncology community. The IASLC proposes 
to improve on the above described limitations, especially 
those relating to PET-CT scanning, in time for the 8th 
edition of  TNM classification. A prospective data set 
has been agreed, funding has been secured for the 7-year 
cycle leading up to the 8th edition. A web-based data col-
lection system is being developed and tested to make data 
submission easier for those who collaborate in this next 
phase. Data collection has been expanded to incorporate 
neuro-endocrine tumours and mesothelioma[23].
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